SCIENCEYE BLOG

Contact

Atherosclerosis

23 min read

Updated on November 2, 2026
Painted cross section of an artery with a pale plaque narrowing a glowing channel of blood

SHARE:

Introduction

Definition

Atherosclerosis is the formation of fibrofatty lesions, made of fat and fibrous tissue, in the artery wall.1 Each lesion is called a plaque, or an atheroma in medical language, and many people know the disease as hardening of the arteries. It causes most heart attacks and many strokes, along with disabling peripheral artery disease.1

Context

Atherosclerosis is far older than modern life. Researchers used computed tomography (CT) to scan 137 mummies from four ancient populations, hunter-gatherers among them. They found probable or definite Atherosclerosis in 34% of the mummies.2 Modern lifestyles shape risk today, but these scans show that the condition itself is not new.

Science took much longer to explain Atherosclerosis. In 1913, the researcher Anitschkow published a paper that placed high blood cholesterol at the center of the process, and his animal work went on to define most of the key steps in how lesions begin and grow.3

Scope

This entry covers the parts of an arterial plaque, the biology that builds it, the evidence for its causes, the tests that find it, and the ways to manage it. It closes with open debates about Atherosclerosis. It explains the science and does not give personal medical advice.

A healthy artery and an artery with plaque Two cross-sections of an artery. On the left, a healthy artery has an even wall and a wide open channel. On the right, a plaque has grown inside the wall and narrows the channel. Build-up inside the artery wall Open channel Healthy artery Artery with plaque plaque
Figure 1. Plaque forms within the artery wall and narrows the channel for blood. The schematic is not to scale.1,4

Detailed Explanation

Atherosclerosis Components

To see what an arterial plaque is, start with the healthy wall. A single layer of endothelial cells lines every blood vessel and forms the first barrier between the blood and the tissues.4 Together with collagen and elastic fibers, this lining makes up the intima, the innermost layer. Beneath it sits the media, with its smooth muscle cells and elastic tissue, and then the outer adventitia.4 The lining does far more than sit in place. It senses mechanical stress and metabolic changes in the blood, and it passes signals to the deeper layers.4 It also keeps the surface from turning sticky and balances opposing signals, such as those that promote or prevent clotting and those that widen or narrow the vessel.4 These duties explain why damage to so thin a layer matters. Plaque builds up in the intima. It therefore grows within the wall itself, rather than settling on the surface like sludge in a pipe.4

The earliest visible lesion is the fatty streak, a collection of lipid inside and between cells.4 Many of those lipid-filled cells are foam cells. They form when immune cells or smooth muscle cells take up cholesterol particles that have been chemically changed. At least half of the foam cells in the human coronary intima come from smooth muscle cells rather than from immune cells.4

Cholesterol is central, yet a mature plaque is far more than a lump of fat. It has a cell-poor, lipid-rich center called the necrotic core, covered by a fibrous cap made by smooth muscle cells.4 Calcium deposits can then form within it, and these deposits resemble bone.4 Table 1 summarizes these parts.

ComponentDescriptionFunction or role
EndotheliumSingle layer of cells lining the arteryBarrier and sensor; its failure starts the disease4
Foam cellsImmune and smooth muscle cells filled with lipidForm the fatty streak, the first sign of disease4
Necrotic coreLipid-rich center with few living cellsGrows as cells die and are not cleared4,5
Fibrous capSmooth muscle cells and the matrix they makeKeeps blood away from the clot-forming core4
Calcium depositsBone-like mineral within the plaqueMark advanced disease and track plaque size4
Table 1. The main components of the artery wall and of plaque.4

Calcium deposits fit the old name, hardening of the arteries, but they can also mislead. The amount of calcium tracks plaque size well, but it does not track how likely a plaque is to break. Other features, such as location and the type of calcification, matter more for that risk.4

Cells and Crystals

Smooth muscle cells change their job as the plaque grows. In a healthy artery they sit in the media and set the width of the vessel. Growth factors from foam cells and endothelial cells draw them into the intima, where they multiply and lay down the matrix of the cap.4

Immune cells in a plaque are not all alike. Once in the intima, monocytes mature into macrophages. Pro-inflammatory types dominate as Atherosclerosis progresses, anti-inflammatory types dominate when it regresses, and macrophages can switch between the two in response to local signals.4 Cholesterol can also form crystals, both inside and outside cells. These crystals appear in advanced lesions and in early plaques, and they stimulate an immune sensor that feeds inflammation.4

Atherosclerosis Variations

Atherosclerosis does not strike arteries at random. Plaques appear mostly at branch points and curves, where blood flow turns disturbed. In these spots, shear stress, the drag of flowing blood on the lining, is low.4 Disturbed flow also lets cholesterol particles linger near the wall and enter it more easily.4 Endothelial cells sense this force and respond to it. In straight segments they line up with the flow, whereas at branch points they swell and look more like cobblestones.4

In Atherosclerosis, size and danger are not the same thing. A plaque that narrows an artery by more than about 70% can limit blood flow during effort, which brings on chest pain or leg pain.4 Yet post-mortem studies suggest that plaques causing only 30% to 40% narrowing are more likely to rupture.4 Early on, the artery also remodels outward. This keeps the channel open but allows the lesion to grow unseen, so a plaque can be large without causing much narrowing.4

Clinical Forms

Atherosclerosis produces different illnesses, depending on the artery it reaches. In the heart it causes coronary artery disease, with chest pain and heart attack. In the arteries serving the brain it can cause ischemic stroke, and in the legs it causes peripheral artery disease.1,4 Doctors group these conditions under the term atherosclerotic cardiovascular disease.

A plaque can also fail in two main ways. In plaque rupture, the fibrous cap tears and exposes the core to the blood.4 In plaque erosion, a clot forms although the cap stays intact. Erosion may lie behind more than one-third of acute coronary syndromes, the sudden blockages of blood flow to the heart.6 A plaque can also grow in steps. When a fissure heals, platelets release signals that thicken the cap, and the lesion gains size and narrows the artery, often with no clinical event.4

Atherosclerosis also differs between women and men. Imaging shows that men develop plaques earlier and carry a greater plaque burden, even after researchers account for risk factors.4 Younger women have lower rates of heart attack than men, but this advantage fades between the ages of 60 and 79, and by age 80 the risk of cardiovascular disease in women exceeds that in men.4 Smoking, high blood pressure, and diabetes also raise the odds of heart attack more in women than in men, by about 1.3, 1.5, and 1.6 times respectively.4

Arteriosclerosis Compared

Atherosclerosis is also distinct from arteriosclerosis, the stiffening of the artery wall. The two names sound alike, and both processes age the arteries, but they are measured differently. A study of 4330 older adults measured Atherosclerosis with the ankle-brachial index, which compares blood pressure at the ankle and the arm. It measured arteriosclerosis with femoral-ankle pulse wave velocity, the speed of the pressure wave along the leg. Both measures tracked overall disease, and the arteriosclerosis measure stayed linked to disease after researchers accounted for the ankle-brachial index and standard risk factors.7 Our entry on arterial stiffness covers that process in depth.

Key points: arterial plaque is a structured lesion inside the artery wall, not a coating on it. It forms mostly where flow is disturbed, and it can fail by rupture or by erosion.

Scientific Basis

Atherosclerosis Mechanisms

Atherosclerosis runs as a sequence, and each step sets up the next. It starts with endothelial dysfunction, the loss of normal function in the artery lining, which comes before plaque forms.8 A healthy lining keeps the vessel in balance. Once it fails, the wall becomes prone to narrowing, lipid entry, sticky white blood cells, platelet activation, and oxidative stress.4 Part of the damage traces to nitric oxide, a molecule made by endothelial cells. It relaxes smooth muscle and limits platelet clumping, inflammation, and abnormal cell growth, so a shortage removes a natural defense.4 Cigarette smoke adds its own harm, because its chemicals damage the endothelium and feed inflammation.4

Next comes the cholesterol. Low-density lipoprotein (LDL) is a particle that carries cholesterol through the blood, and plaque probably cannot develop without it.1 When levels in the blood are high, more LDL cholesterol crosses the lining into the intima.4 There it is held in place and chemically modified, chiefly by oxidation.4

The body then treats the modified particles as a threat. Activated endothelial cells recruit monocytes, a type of white blood cell, which roll along the lining, stick to it, and move into the intima.4 Inside the wall, these cells and nearby smooth muscle cells take up the modified particles and become foam cells. Inflammatory signals follow, and the fatty streak, the first sign of Atherosclerosis, appears.4

From Lesion to Clot

Over time, the lesion changes character as Atherosclerosis advances. A necrotic core forms, and fibers cover it to make the fibrous cap. Together they mark advanced disease, a stage at which plaque is unlikely to shrink back.4 The core grows partly because the cleanup system breaks down. Normally, immune cells remove dead cells by a process called efferocytosis. In Atherosclerosis this process fails, so dead tissue builds up, inflammation rises, and the plaque becomes more prone to rupture or erosion.5

The final step in Atherosclerosis is the clot. Dying smooth muscle cells make less matrix, and released enzymes weaken the cap further.4 A plaque is considered vulnerable when it has a large necrotic core, a thin cap, and strong inflammation.4 If the cap breaks, the blood meets the core. Platelets gather, tissue factor from the core sets off clotting, and threads of fibrin, an insoluble protein, bind the clot together.4 Some ruptures heal without symptoms and simply leave a larger lesion. When a clot blocks an artery completely or almost completely, the result is a heart attack or a stroke.4 Figure 2 shows this sequence.

The stages of plaque Five stages in a column, highlighted one at a time in a repeating 8-second loop: lining damaged, cholesterol enters the wall, foam cells form, fibrous plaque grows, and rupture and clot. From damaged lining to clot 1. Lining damaged 2. Cholesterol enters the wall 3. Foam cells form 4. Fibrous plaque grows 5. Rupture and clot
Figure 2. The main stages of Atherosclerosis, from endothelial dysfunction to plaque rupture.4

This sequence answers a common question: if cholesterol matters so much, why do people with normal cholesterol have heart attacks? LDL cholesterol is needed for plaque, but it is not the only force at work. High blood pressure, smoking, and diabetes also raise risk.1 Inflammatory pathways link these traditional risk factors, and newer ones, to the changed behavior of cells in the artery wall.9 Our entry on systemic inflammation explains those pathways.

Atherosclerosis Evidence

Correlation cannot prove cause, because people with high cholesterol may differ in many other ways. Genetic studies help with this problem. People inherit gene variants at random, much as patients in a trial are assigned to treatment at random. Comparing people with naturally high or low LDL cholesterol therefore works a little like a trial. This method is called Mendelian randomization. A European consensus panel weighed this evidence alongside cohort studies and randomized trials. Across more than 2 million participants and over 150,000 cardiovascular events, risk rose steadily with exposure to LDL cholesterol.10 The panel concluded that LDL causes atherosclerotic cardiovascular disease.10

Randomized trials of treatments for Atherosclerosis tell the same story. They report a rate ratio or a hazard ratio. Both compare event rates between the treated and control groups, and a value below 1 means fewer events with treatment. Each comes with a 95% confidence interval (CI), the range of values the data support. A pooled analysis of 26 trials and about 170,000 participants found that each 1.0 mmol/L fall in LDL cholesterol cut major vascular events by about a fifth (rate ratio 0.78; 95% CI 0.76 to 0.80).11 The analysis found no threshold within the range studied, and the benefit extended to people who started below 2 mmol/L.11 Our entry on meta-analysis explains how such pooling works.

A later trial pushed levels lower still. In 27,564 patients already taking statins, the drug evolocumab lowered LDL cholesterol from a median of 2.4 mmol/L to 0.78 mmol/L. It also reduced the combined rate of cardiovascular death, heart attack, stroke, hospital care for unstable angina, and procedures to reopen coronary arteries (hazard ratio 0.85; 95% CI 0.79 to 0.92).12

Lipoprotein(a), a separate cholesterol-carrying particle, has also earned a causal label. Genetic and population studies of hundreds of thousands of people support a continuous link with cardiovascular outcomes, even at very low LDL cholesterol.13 Table 2 lists the key studies.

StudyYearKey findingDigital object identifier (DOI)
Baigent et al.2010Each 1.0 mmol/L fall in LDL cholesterol cut major vascular events by about a fifth10.1016/S0140-6736(10)61350-5
Thompson et al.2013Atherosclerosis found in 34% of 137 mummies from four ancient populations10.1016/S0140-6736(13)60598-X
Ference et al.2017Genetic, cohort, and trial evidence: LDL causes the disease10.1093/eurheartj/ehx144
Sabatine et al.2017Lowering LDL cholesterol to 0.78 mmol/L further reduced events10.1056/NEJMoa1615664
Kronenberg et al.2022Lipoprotein(a) is a causal risk factor10.1093/eurheartj/ehac361
Table 2. Key studies of the history and causes of Atherosclerosis.

Current Understanding

The core model of Atherosclerosis now has wide support. Both the 2025 European update and the 2026 American guideline start from the same premise: LDL cholesterol and related particles cause Atherosclerosis, and benefit depends on earlier, deeper, and sustained reduction.14 They organize care differently, however. The European approach ties risk categories more tightly to set LDL cholesterol goals, while the American one gives more weight to lifetime risk, coronary artery calcium, and shared decisions.14

The risk picture keeps shifting around that core. Atherosclerosis is no longer concentrated in Western countries, and it now affects younger people and more women than before.9 Researchers have also questioned the protective role of high-density lipoprotein. They now study triglyceride-rich particles, along with disturbed sleep, physical inactivity, air pollution, and environmental stress.9 One striking addition is clonal hematopoiesis. In this common, age-related condition, mutations in blood stem cells raise the risk of cardiovascular disease.9

Key points: Atherosclerosis runs from a damaged lining to a clot. Genetic studies and randomized trials agree that LDL cholesterol is a cause, and inflammation links many risk factors to the artery wall.

Clinical and Practical Applications

Atherosclerosis Relevance

Atherosclerosis matters clinically because it gives little warning. It starts early in life and progresses silently for decades.15 Research places its start in preadolescence.16 One long-running cohort enrolled 4184 middle-aged adults without symptoms and tracks arterial plaque in several parts of the body with imaging.15 Feeling well therefore says little about whether Atherosclerosis is present.

The cost of silent Atherosclerosis is large. Cardiovascular disease causes more than 1 of every 4 deaths in the United States. In 2019, coronary heart disease caused an estimated 558,000 of those deaths, and ischemic stroke about 109,000.17 The damage also reaches beyond the heart, as our post on the heart-brain connection describes. Our entry on healthspan looks at years lived in good health.

Atherosclerosis Measurement

Several tests can reveal Atherosclerosis, and they differ in what they add. The coronary calcium score uses CT to measure calcified plaque in the heart arteries. In 6722 adults from four racial or ethnic groups, a score above 300 carried 9.67 times the adjusted risk of a coronary event, compared with no calcium.18 CT coronary angiography goes further and shows the arteries themselves. In 4146 patients with stable chest pain, adding it to standard care lowered the 5-year rate of coronary death or nonfatal heart attack from 3.9% to 2.3% (hazard ratio 0.59; 95% CI 0.41 to 0.84). Those patients also started more preventive treatment.19

Simpler tests for Atherosclerosis have a place too. The ankle-brachial index is easy to measure, and a value of 0.90 or below signals disease.7 Pooled data on 48,294 adults linked a low value to about twice the 10-year risk within each standard risk category.20 Our post on pulse wave velocity covers a related measure. Not every test earns its place, however. Carotid wall thickness, measured by ultrasound, added only a small gain to risk prediction, one unlikely to matter in practice.21 A test helps only when it changes care, and Table 3 compares them. Flow-mediated dilation, an ultrasound test, is the standard tool for assessing endothelial function, and a reduced result is an early marker of Atherosclerosis.8

MethodNormal range or thresholdClinical significance
Coronary calcium scoreZero means no detected calcium; the top risk group scored above 300Predicted coronary events beyond standard risk factors18
CT coronary angiographyShows plaque and narrowing rather than a single numberAdded to standard care, lowered 5-year coronary death or heart attack19
Ankle-brachial indexNormal 1.11 to 1.40; low at 0.90 or belowImproved risk prediction beyond a standard risk score20
Carotid wall thicknessNo clinical threshold reported in the sourceSmall gain, unlikely to matter in practice21
Flow-mediated dilationLower values mark poorer endothelial functionEarly marker that can predict future events8
Table 3. Common tests for Atherosclerosis and what they add.

Atherosclerosis Management

Managing Atherosclerosis centers on risk factors and medicines. Diet has trial evidence: among 7447 people at high risk, a Mediterranean diet with extra-virgin olive oil (hazard ratio 0.69; 95% CI 0.53 to 0.91) or nuts (hazard ratio 0.72; 95% CI 0.54 to 0.95) lowered major cardiovascular events compared with a reduced-fat diet. The authors republished these results in 2018 after finding flaws in how some participants were assigned.22 Our post on supplements and diet looks at this choice.

Movement matters as well. Among 27,055 women, risk fell steadily with activity, reaching 41% lower at the highest level. Known risk factors explained much of the gain, led by inflammatory and clotting markers and by blood pressure.23 Sedentary time is a separate concern. A Meta-Analysis linked it to cardiovascular death after allowing for Physical Activity (hazard ratio 1.18; 95% CI 1.11 to 1.26), although most studies relied on self-report.24 Researchers still lack the trials needed to write specific guidance on sitting.25 Our posts on stretching for heart health, sitting less, and exercise for diabetes offer practical detail.

Stopping smoking is among the most important steps at any age, and it has been linked to less progression of carotid plaque.4

Medicines and Procedures

Medicines lower risk further.11 The United States Preventive Services Task Force recommends a statin for adults aged 40 to 75 years who have at least one cardiovascular risk factor and a 10-year risk of 10% or more. It advises clinicians to offer one selectively at a 10-year risk of 7.5% to below 10%, where the likely benefit is smaller.17 Care is not always equal, though: recent studies found that clinicians offer statins to women at a lower rate than to men.4

A stent can seem like the obvious fix, and for stable disease the evidence says otherwise. In 5179 patients with stable coronary disease and moderate or severe ischemia, starting with a procedure did not reduce cardiovascular events or death from any cause over a median of 3.2 years, compared with starting on medicine alone. At 5 years, the cumulative event rate was 16.4% with a procedure first and 18.2% with medicine first (difference of 1.8 percentage points; 95% CI, 4.7 lower to 1.0 higher).26 That result applies to stable disease, not to a heart attack in progress. Figure 3 brings these options together.

Options linked to lower cardiovascular risk Four boxes, labeled diet, Physical Activity, less sitting, and lipid-lowering medicine, each point to one box labeled lower cardiovascular risk. Options linked to lower risk Diet Physical Activity Less sitting Lipid-lowering medicine Lower cardiovascular risk
Figure 3. Options linked to lower cardiovascular risk. The evidence for Physical Activity and less sitting is observational.11,22,23,24

Key points: symptoms arrive late, so feeling well says little. Tests differ in what they add. Risk-factor care and medicines lower risk, while a procedure did not lower events in stable disease.

Controversies and Limitations

Atherosclerosis Debates

Inflammation is a real target in Atherosclerosis, but the trials disagree. In 10,061 patients with a previous heart attack, canakinumab at 150 mg lowered recurrent events (hazard ratio 0.85; 95% CI 0.74 to 0.98) without lowering lipids, at the cost of more fatal infections.27 Low-dose colchicine helped 5522 patients with chronic coronary disease (hazard ratio 0.69; 95% CI 0.57 to 0.83).28 Yet in 7062 patients after a heart attack, it made no difference (hazard ratio 0.99; 95% CI 0.85 to 1.16).29

Athletes pose another puzzle for Atherosclerosis research. Male masters endurance athletes had more plaque than sedentary men with similar risk (44.3% versus 22.2%), though most of it was calcified. The authors called the meaning uncertain and suggested this plaque may be more stable.30

Limitations

Some practical questions about Atherosclerosis remain open. The evidence is insufficient to judge statins for primary prevention at age 76 or older.17 Trials of specific lipoprotein(a)-lowering drugs still need to confirm clinical benefit.13 Laboratory evidence has gaps too. In one review of 771 preclinical articles, fewer than a quarter studied both males and females, so sex differences remain poorly understood.4 Ideas about how plaques trigger clots are also changing, and research has moved beyond the vulnerable plaque concept.9 These gaps concern how to act on the causal model of Atherosclerosis rather than whether it holds.

References

  1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z
  2. Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet. 2013;381(9873):1211-22. doi:10.1016/S0140-6736(13)60598-X
  3. Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of Atherosclerosis. J Lipid Res. 2013;54(11):2946-9. doi:10.1194/jlr.R043414
  4. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23(6):3346. doi:10.3390/ijms23063346
  5. Adkar SS, Leeper NJ. Efferocytosis in Atherosclerosis. Nat Rev Cardiol. 2024;21(11):762-79. doi:10.1038/s41569-024-01037-7
  6. Meteva D, Seppelt C, Abdelwahed YS, Leistner DM. Distinct pathological mechanisms distinguish acute coronary syndrome caused by plaque erosion from plaque rupture. Curr Opin Cardiol. 2021;36(6):793-7. doi:10.1097/HCO.0000000000000912
  7. Stone K, Fryer S, Faulkner J, Meyer ML, Heffernan K, Kucharska-Newton A, et al. Associations of lower-limb Atherosclerosis and arteriosclerosis with cardiovascular risk factors and disease in older adults: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2021;340:53-60. doi:10.1016/j.atherosclerosis.2021.10.014
  8. Stoner L, Sabatier MJ. Use of ultrasound for non-invasive assessment of flow-mediated dilation. J Atheroscler Thromb. 2012;19(5):407-21. doi:10.5551/jat.11395
  9. Libby P. The changing landscape of Atherosclerosis. Nature. 2021;592(7855):524-33. doi:10.1038/s41586-021-03392-8
  10. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi:10.1093/eurheartj/ehx144
  11. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a Meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi:10.1016/S0140-6736(10)61350-5
  12. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664
  13. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-46. doi:10.1093/eurheartj/ehac361
  14. Finocchiaro S, Mauro MS, Bordonaro C, Bujak K, Cosentino C, Cutore L, et al. Comparison of the 2025 ESC/EAS and 2026 ACC/AHA guidelines for dyslipidemia management. Eur J Prev Cardiol. 2026. doi:10.1093/eurjpc/zwag413
  15. Ibanez B, Fernández-Ortiz A, Fernández-Friera L, García-Lunar I, Andrés V, Fuster V. Progression of Early Subclinical Atherosclerosis (PESA) study: JACC focus seminar 7/8. J Am Coll Cardiol. 2021;78(2):156-79. doi:10.1016/j.jacc.2021.05.011
  16. Stoner L, Weatherall M, Skidmore P, Castro N, Lark S, Faulkner J, et al. Cardiometabolic risk variables in preadolescent children: a factor analysis. J Am Heart Assoc. 2017;6(10):e007071. doi:10.1161/JAHA.117.007071
  17. Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022;328(8):746-53. doi:10.1001/jama.2022.13044
  18. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336-45. doi:10.1056/NEJMoa072100
  19. Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924-33. doi:10.1056/NEJMoa1805971
  20. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a Meta-Analysis. JAMA. 2008;300(2):197-208. doi:10.1001/jama.300.2.197
  21. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a Meta-Analysis. JAMA. 2012;308(8):796-803. doi:10.1001/jama.2012.9630
  22. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389
  23. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical Activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116(19):2110-8. doi:10.1161/CIRCULATIONAHA.107.729939
  24. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and Meta-Analysis. Ann Intern Med. 2015;162(2):123-32. doi:10.7326/M14-1651
  25. Stoner L, Barone Gibbs B, Meyer ML, Fryer S, Credeur D, Paterson C, et al. A primer on repeated sitting exposure and the cardiovascular system: considerations for study design, analysis, interpretation, and translation. Front Cardiovasc Med. 2021;8:716938. doi:10.3389/fcvm.2021.716938
  26. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395-407. doi:10.1056/NEJMoa1915922
  27. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. doi:10.1056/NEJMoa1707914
  28. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-47. doi:10.1056/NEJMoa2021372
  29. Jolly SS, d’Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, et al. Colchicine in acute myocardial infarction. N Engl J Med. 2024;392(7):633-42. doi:10.1056/NEJMoa2405922
  30. Merghani A, Maestrini V, Rosmini S, Cox AT, Dhutia H, Bastiaenan R, et al. Prevalence of subclinical coronary artery disease in masters endurance athletes with a low atherosclerotic risk profile. Circulation. 2017;136(2):126-37. doi:10.1161/CIRCULATIONAHA.116.026964

External Resources

Leave a Reply

Your email address will not be published. Required fields are marked *